GPR120 agonists improved insulin resistance in long-term administration (≥8 weeks) (Oliveira et al., 2015; Jia and Liu, 2022), but did not ameliorate postprandial hyperglycemia by single oral administration 30 min before glucose load in mice (Li et al., 2017). The gene discussed is FFAR4; the disease is Hyperglycemia.